The antisense oligonucleotide (ASO) tofersen (Qalsody; Biogen) is the first approved therapy for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the SOD1 gene (SOD1-ALS). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.